Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
Matsubara N, et al.
December 2023
Authors and Affiliates
Nobuaki Matsubara 1, Shota Kusuhara 2, Noboru Yamamoto 3, Kazuki Sudo 3, Masahiko Yanagita 4,5, Kosho Murayama 6, Hisashi Kawasumi 4, Deanna L Russell 7, Da Yin 8, Toshio Shimizu 3,9;
1 Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. nmatsuba@east.ncc.go.jp.
2 Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
3 Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
4 Research & Development, AstraZeneca K.K., Tokyo, Japan.
5 Oncology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
6 Research & Development, AstraZeneca K.K., Osaka, Japan.
7 Translational Medicine, Early Oncology, Oncology R&D, AstraZeneca Pharmaceuticals, Boston, MA, USA.
8 Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.
9 Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Graduate School of Medicine, Wakayama Medical University Hospital, Wakayama, Japan.